NCT02043756View on ClinicalTrials.gov

Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

August 31, 2013

Conditions
Neoplasms
Interventions
DRUG

Mitoxantrone Hydrochloride Liposome

6-16mg/m2, IV ,one time of each 28 day cycle,3 cycles

DRUG

Mitoxantrone

10mg/m2, IV ,on day 1 of each 28 day,3 cycles

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT02043756 - Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection | Biotech Hunter | Biotech Hunter